An insertion/deletion polymorphism in the CD3γ promoter was linked with increased hepatocellular carcinoma incidence (74), and another (rs3181259T>C) in CD3δ was linked to recurrence in non-small cell lung cancer (NSCLC) (75). Here, CD3D is linked to non-small cell lung carcinoma.